During the 43rd J.P. Morgan Annual Healthcare Conference last month, Areteia Therapeutics took centre stage, presenting a detailed review of its achievements in 2024 and outlining its 2025 plans. Led by CEO Jorge Bartolome, the company highlighted its ongoing work on dexpramipexole dihydrochloride, the first oral therapy targeting eosinophilic asthma, and shared key milestones that may secure the company’s position as a frontrunner in the respiratory health space.

A major focus of the presentation was the progress of the EXHALE clinical trial programme. Significant advancements have been made in the pivotal Phase III asthma trials (EXHALE-2, EXHALE-3, and EXHALE-4), with EXHALE-4 now fully enrolled and topline results expected in the third quarter of 2025. Additionally, the SUSPIRE-1 trial, investigating the efficacy of dexpramipexole in treating chronic obstructive pulmonary disease (COPD), is fully enrolled, with data readouts anticipated later in the year. Areteia’s strategic positioning within the asthma and COPD markets was another key topic, emphasising dexpramipexole’s potential as a first-in-class oral therapy in a biologics-dominated market. If approved, the therapy potentially could transform the treatment landscape by addressing the unmet needs of patients facing barriers to injectable treatments.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Bartolome also highlighted dexpramipexole’s strong differentiation within the competitive landscape. Data from Phase II trials demonstrated therapeutic efficacy similar to biologics, including significant reductions in blood eosinophils and notable improvements in lung function (FEV1). Bartolome expressed confidence in the drug’s ability to expand the adoption of advanced targeted therapies and potentially redefine the treatment paradigm for severe asthma. Additionally, Areteia’s comprehensive pipeline spans over 2,800 patients across more than 30 countries, supported by over 600 trial sites specialising in respiratory health. The company is actively preparing for regulatory submissions, enhancing formulations, and initiating paediatric studies to ensure long-term value creation and alignment with US Food and Drug Administration and European Medicines Agency guidelines.

Closing the presentation, Bartolome offered a forward-looking perspective on Areteia’s mission to revolutionise respiratory care. Backed by $425m in Series A funding and a seasoned leadership team, the company is poised to address significant medical and economic challenges in asthma and COPD. With dexpramipexole at the forefront, Areteia aims to drive innovation and expand its pipeline to deliver life-changing therapies for patients worldwide. As 2025 unfolds, the anticipated data readouts from pivotal trials are expected to validate the transformative potential of dexpramipexole and mark a turning point in the treatment of eosinophilic airway diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.